Canaccord raised the firm’s price target on Exagen (XGN) to $15 from $11 and keeps a Buy rating on the shares. The firm updated its model ahead of Q3 results noting that the life science tools secot remains challenged amid multiple headwinds including tariffs, funding uncertainty, and China issues.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XGN: